On August 31, WUXI BIO fell 4.4% in regular trading, trading at HK$49.82/share, with turnover of HK$260 million. The decline reflects continued profit-taking pressure following the company's strong interim results released on August 25.

The company reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year, with adjusted net profit attributable to shareholders surging 38.4%. Management also raised full-year revenue growth guidance to 15%-18%. Multiple investment banks subsequently upgraded their target prices, with CICC and CMB International both raising targets to HK$60, Daiwa to HK$59, and Morgan Stanley to HK$57.

However, the earnings beat and upgraded outlook had been largely priced in during the prior rally. A sector-wide pullback began on August 27, and selling pressure from profit-taking has persisted. Peers including WUXI APPTEC and WUXI XDC also declined, with the broader Life Sciences Tools & Services sector trending weak. TIGERMED was the sole outlier, rising 11.01%, while INSILICO fell 3.71%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)